Table 2 Base-case population-level results and incremental cost-effectiveness analysis of continuing the QOF vs. stopping the QOF
From: Modelling the cost-effectiveness of pay-for-performance in primary care in the UK
| Â | Undiscounted | Discounted | Â | ||||
|---|---|---|---|---|---|---|---|
life years | QALYs | QOF-related costs | life years | QALYs | QOF-related costs | ICER (£/QALY) | |
Stopping the QOF | 78,805,931 | 59,562,301 | £0 | 52,426,797 | 39,966,375 | £0 | Reference |
Continuing the QOF | 79,433,681 | 60,237,416 | £25,881,916,480 | 52,750,331 | 40,316,707 | £17,293,239,670 | 49,362 |
Delta | 627,750 | 675,114 | £25,881,916,480 | 323,534 | 350,332 | £17,293,239,670 | – |